Atropine sulfate monohydrate

Catalog No.S2130

For research use only.

Atropine sulfate monohydrate is a competitive antagonist for the muscarinic acetylcholine receptor, used to decrease the production of saliva and secretions of the airway prior to surgery.

Atropine sulfate monohydrate Chemical Structure

CAS No. 5908-99-6

Selleck's Atropine sulfate monohydrate has been cited by 1 Publication

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description Atropine sulfate monohydrate is a competitive antagonist for the muscarinic acetylcholine receptor, used to decrease the production of saliva and secretions of the airway prior to surgery.
Targets
mAChR [1]
2.5 nM
In vitro

Atropine increases the release of the neurotransmitter dopamine into the superfusate in vitro at 100-500 mM and into the vitreous in vivo at 250 mg. Atropine induces spreading depression (SD) in the in vitro preparation. Atropine reduces the ERG b- and d-wave, leads to damped oscillations of RPE potentials, and reverses the ERG c-wave. Atropine suppresses myopia only at doses at which severe nonspecific side effects are observed in the retina. [1]

In vivo Atropine (1.0 mg/kg, i.p.), but not methylatropine (1.0 mg/kg, i.p.), prevents the enhancement of retention induced by both doses of the anticholinesterase when given immediately after training in mice. [2] Atropine administration effectively prevents bradycardia and second-degree heart block but induces pulsus alternans and hypertension in dogs. [3] Atropine has no effect on handling-induced acetylcholine output in the presence of 10 nM neostigmine, but causes greater and longer increases in the presence of 100 nM and 1000 nM neostigmine in rats. [4] Atropine not only blocks the rapid eye movement (REM) sleep increases induced by CGS but it also tends to decrease REM sleep compared to atropine preceding saline in rats. [5] Atropine decreases the time to exhaustion by 67% in intact rats and by 96.2% in adrenodemedullated (ADM) and also reduces the exercise-induced pituitary prolactin (PRL) release in both intact (50%) and ADM rats (90%). [6]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 694.83
Formula

2(C17H23NO3).H2O.H2SO4

CAS No. 5908-99-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05468125 Not yet recruiting Procedure: guidance Hypotension|Cesarean Section Complications Suez Canal University August 1 2022 Not Applicable
NCT05164367 Recruiting Drug: Atropine sulfate gel (0.01%) Cerebral Palsy|Sialorrhea University of Utah June 1 2022 Early Phase 1
NCT05160207 Recruiting -- Tracheal Intubation|Airway Management|Heart Rate Universitätsklinikum Hamburg-Eppendorf November 4 2021 --
NCT04752904 Recruiting Device: ClearSight System Cesarean Section Complications|Hypotension Seoul National University Hospital April 27 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Atropine sulfate monohydrate | Atropine sulfate monohydrate ic50 | Atropine sulfate monohydrate price | Atropine sulfate monohydrate cost | Atropine sulfate monohydrate solubility dmso | Atropine sulfate monohydrate purchase | Atropine sulfate monohydrate manufacturer | Atropine sulfate monohydrate research buy | Atropine sulfate monohydrate order | Atropine sulfate monohydrate mouse | Atropine sulfate monohydrate chemical structure | Atropine sulfate monohydrate mw | Atropine sulfate monohydrate molecular weight | Atropine sulfate monohydrate datasheet | Atropine sulfate monohydrate supplier | Atropine sulfate monohydrate in vitro | Atropine sulfate monohydrate cell line | Atropine sulfate monohydrate concentration | Atropine sulfate monohydrate nmr